权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Development of a small-molecule that enhances tripartite synapses for Alzheimers disease

开发一种增强阿尔茨海默病三联突触的小分子

基本信息

批准号：
10045319
负责人：
CHIEN-LIANG GLENN LIN
金额：
$ 155.25万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-15 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10045319
关键词：
Alzheimer&apos s Disease Alzheimer&apos s disease model Alzheimer&apos s disease pathology Alzheimer&apos s disease patient Astrocytes Canis familiaris Clinical Clinical Research Clinical Trials Cognitive Development Disease Dose Drug Compounding Event Excitatory Amino Acid Transporter 2 Formulation Foundations Funding Genetic Glutamate Transporter Glutamates Grant Hippocampus (Brain)Human Hyperactive behavior Institutional Review Boards Investigational Drugs Long-Term Potentiation Maintenance Mediating Memory Memory impairment Mus Nerve Degeneration Neurofibrillary Tangles Pathogenesis Pathology Pharmaceutical Preparations Pharmacology Phase I Clinical Trials Play Polymorph Process Production Pyridazines Rattus Research Role Safety Senile Plaques Series Sodium Chloride Solubility Specificity Structure Symptoms Synapses System Toxic effect Toxicology Translational Activation base candidate selection cognitive function drug discovery extracellular first-in-human functional plasticity improved lead optimization meetings method development mouse model novel novel therapeutic intervention novel therapeutics preclinical development prevent protein expression protein function screening small molecule tau phosphorylation therapeutic target

项目摘要

Project Summary The best correlate of memory deficits in Alzheimer’s disease (AD) patients is not Aβ plaque burden or neurofibrillary tangles, but synapse loss, which is thought to occur early in the disease process before the onset of clinical symptoms. We have developed a novel compound called M3 that can effectively enhance structural and functional plasticity of synapses. This compound has been proved to provide significant benefits in two mouse models of AD (APPSw/Ind mice and rTg4510 mice), including improved cognitive functions, restored synaptic integrity, reduced neurodegeneration, reduced tau phosphorylation and neurofibrillary tangles, and reduced amyloid plaques. M3 has excellent potency, solubility, stability, specificity, and thus far no overt safety concerns. M3 meets all Late Stage Entry Criteria. In Year 1, we will focus on IND-enabling studies and IND preparation and filing. Our milestones are (i) completion of IND-enabling studies, (ii) production of a GMP batch for clinical studies, and (iii) active IND. In Year 2, we will focus on a single ascending dose (SAD) study. Our milestones are (i) IRB approval, (ii) completion of SAD study, and (iii) MTD and single dose PK established. In Year 3, we will focus on a multiple ascending dose (MAD) study. Our milestones are (i) completion of MAD study and (ii) MTD and repeat dose PK established.

项目摘要阿尔茨海默病（AD）患者记忆缺陷的最佳相关因素不是Aβ斑块负荷或神经原纤维缠结，但突触丢失，这被认为发生在疾病过程的早期，临床症状的出现。我们开发了一种名为M3的新型化合物，增强突触的结构和功能可塑性。该化合物已被证明提供在两种AD小鼠模型（APPSw/Ind小鼠和rTg 4510小鼠）中的显著益处，包括改善认知功能，恢复突触完整性，减少神经变性，减少tau磷酸化和神经纤维缠结，减少淀粉样斑块。M3具有优异的效力、溶解性、稳定性，特异性，到目前为止没有明显的安全性问题。M3符合所有后期阶段进入标准。在第一年，我们将专注于IND启动研究和IND准备和备案。我们的里程碑是（i）完成 IND使能研究，（ii）生产用于临床研究的GMP批次，以及（iii）活性IND。在第2年，我们将重点关注单次递增剂量（SAD）研究。我们的里程碑是（i）IRB批准，（ii）完成 SAD研究，和（iii）确定MTD和单次给药PK。在第三年，我们将重点关注倍数递增剂量（MAD）研究。我们的里程碑是（i）完成MAD研究和（ii）MTD和重复确定的剂量PK。